Re: Irinotecan-Related Cholinergic Syndrome Induced by Coadministration of Oxaliplatin
Valencak et al. (1) have recently reported a case of cholinergic syndrome in a phase II study of oxaliplatin combined with CPT-11.
The patient presented the adverse event when CPT-11 was given 1 hour after oxaliplatin, while no side effects were observed when CPT-11 was given 1 day after oxaliplatin. This anecdotal episode with two positive rechallenges led the authors to suggest that there is a potential interaction between the two drugs.
The CPT-11/oxaliplatin combination has been explored in phase I studies in France, and preliminary results have demonstrated it to be a safe regimen and active in patients with 5-fluorouracilresistant colorectal cancer. More than 50 patients have been treated with over 250 cycles of this therapy given every 2 or 3 weeks (2,3). We have not seen any evidence of enhanced incidence or severity of CPT-11-related toxicity. No pharmacokinetic interaction between the two agents has been detected (4). The only finding concerning increased toxicity was the observation of severe CPT-11-related toxicity (neutropenia and/or diarrhea) in two patients with Gilbert's syndrome (5,6). With a strong pharmacologic rationale, we considered that this phenomenon was attributable to impaired metabolism of CPT-11's active metabolite, SN-38, in patients with deficient hepatic glucuronidating activity.
Hyperacute cholinergic syndrome has been well described, although it is variable in its pharmacodynamics (rate of onset and severity); it has been attributed to the piperidine structure of the CPT-11 molecule, which mimics a cholinergic drug when liberated by esterases to form SN-38 (7).
No increase in the incidence or severity of cholinergic syndrome has been observed in the French trials. However, all patients in these trials received 0.25 mg of prophylactic atropine, given subcutaneously a few minutes before CPT-11, as is customary in many centers that routinely administer CPT-11 according to the European thrice-weekly schedule.
Although the preliminary recommended dose for the combination of CPT-11 and oxaliplatin is 60% of the single-agent recommended dose for either agent, so far we do not have evidence of enhanced cholinergic reaction with this combination. 
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Re: Gene Therapy Strategies for Tumor Antiangiogenesis
In their interesting and thorough review of antiangiogenic gene therapy, Kong and Crystal (1) argue for targeting only tumor-associated vessels and not targeting normal angiogenesis. But in some settings, it also might be of value to target normal angiogenesis.
Gene therapy, the delivery of genes by gene carriers (i.e., transfer vectors) or antiangiogenesis therapy, the administration of antiangiogenic drugs themselves to solid tumors, may be hampered in tumors with low perfusion. We have worked with experimental tumors implanted into the livers of rats. These tumors, as human liver cancers, have a predominantly arterial vascular supply. Temporary hepatic arterial occlusion for 2 hours renders the main part of the experimental tumor necrotic without development of collaterals. However, tumor regrowth takes place in the periphery (2, 3) . Outside the peripheral necrosis of the tumor, granulation tissue with presumably normal capillaries appear, as around all types of necrosis. Cell division (i.e., mitosis) occurs in these capillaries and, of course, in vessels in the regrowing tumor. Therefore, it appears to be of value that, in this setting and in other settings with emerging granulation tissue around the tumor, the antiangiogenic genes and/or drugs are effective against host capillaries as well as against tumor vessels. We do not know if extrahepatic spread from the liver might be influenced by such treatment.
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